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Am J Physiol Endocrinol Metab 295: E380–E384, 2008. First published
June 3, 2008; doi:10.1152/ajpendo.00780.2007.—Obstructive sleep
apnea syndrome (OSAS) increases the risk of cardiovascular events.
Sympathetic nervous system and hypothalamic-pituitary-adrenal
(HPA) axis activation may be the mechanism of this relationship. The
aim of this study was to evaluate HPA axis and ambulatory blood
pressure monitoring in obese men with and without OSAS and to
determine whether nasal continuous positive airway pressure therapy
(nCPAP) influenced responses. Twenty-four-hour ambulatory blood
pressure monitoring and overnight cortisol suppression test with 0.25
mg of dexamethasone were performed in 16 obese men with OSAS
and 13 obese men controls. Nine men with severe apnea were
reevaluated 3 mo after nCPAP therapy. Body mass index and blood
pressure of OSAS patients and obese controls were similar. In OSAS
patients, the percentage of fall in systolic blood pressure at night (P
0.027) and salivary cortisol suppression postdexamethasone (P 
0.038) were lower, whereas heart rate (P  0.022) was higher
compared with obese controls. After nCPAP therapy, patients showed
a reduction in heart rate (P 0.036) and a greater cortisol suppression
after dexamethasone (P  0.001). No difference in arterial blood
pressure (P  0.183) was observed after 3 mo of nCPAP therapy.
Improvement in cortisol suppression was positively correlated with an
improvement in apnea-hypopnea index during nCPAP therapy (r 
0.799, P  0.010). In conclusion, men with OSAS present increased
postdexamethasone cortisol levels and heart rate, which were recov-
ered by nCPAP.
sleep disorders; low-dose dexamethasone test; ambulatory blood pres-
sure monitoring
OBSTRUCTIVE SLEEP APNEA SYNDROME (OSAS) is receiving in-
creased attention because it seems to be associated with a
variety of long-term consequences, such as high rates of
morbidity and mortality, mostly due to cardiovascular disease
(23). Although obesity is the main risk factor for OSAS (39),
it has been demonstrated that OSAS may increase the risk for
hypertension, myocardial infarction, congestive heart failure,
and stroke independently of obesity. Continuous positive air-
way pressure (CPAP) therapy is the treatment of choice for
patients with moderate-to-severe OSAS, since it is highly
effective in improving nocturnal hypoxia and sleep fragmen-
tation, enhancing the quality of life and reducing many cardio-
vascular complications related to OSAS. However, the lack of
acceptance and inadequate adherence to CPAP therapy remain
the major causes of sleep apnea treatment failure (10, 20, 21,
31, 32).
The mechanisms proposed to explain the increased cardio-
vascular disease in obstructive sleep apnea are under assess-
ment. It is speculated that recurrent episodes of upper airway
constriction, progressive hypoxemia, and sleep fragmentation
may result in neural and metabolic changes, including activa-
tion of peripheral sympathetic activity, inflammatory path-
ways, and hypothalamic-pituitary-adrenal (HPA) axis, impair-
ment of insulin sensitivity, and generation of reactive oxygen
species, which could predispose to vascular damage (16, 26,
27, 34).
Sympathetic nervous system has been well demonstrated to
be activated in sleep apnea patients by investigating muscle
sympathetic nerve activity, heart rate variability, blood, and
urinary catecholamine levels (2). In contrast, there are a limited
number of studies that assess the effects of obstructive sleep
apnea on cortisol secretion (9, 12, 13, 18, 35). Some studies
show an elevation of cortisol levels (13, 18, 35) in patients with
OSAS, whereas others do not (9, 12).
The aim of the present study was to evaluate HPA axis, 24-h
heart rate, and blood pressure values in severely obese patients
with and without OSAS and to assess whether OSAS treatment
with nasal CPAP influenced responses.
MATERIALS AND METHODS
Twenty-nine obese men who were on the waiting list for bariatric
surgery were consecutively recruited from the Obesity Outpatient
Clinic and Sleep Disorders Center of the Federal University of Sao
Paulo. These patients, aged from 18 to 65 yr and with body mass
index between 35 and 60 kg/m2, submitted to polysomnography
recordings and were classified according to their apnea-hypopnea
index (AHI) in two different groups: AHI5 events/h, obese controls
(n  13); or AHI 10 events/h, OSAS patients (n  16).
Exclusion criteria included history of smoking, sleep apnea treat-
ment, cardiovascular disease, malignant tumors, thyroid disorders, or
severe depression, subjects with diabetes mellitus, chronic renal, or
hepatic failure, and use of medication that could potentially affect
sympathetic nervous system or steroid hormone secretion (alcohol,
psychotropics, steroids, sympathomimetics, -blockers) and hepatic
enzyme inducers such as carbamazepine, phenytoin, phenobarbitone,
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and rifampicin, which reduce plasma dexamethasone concentrations
(17). Antihypertensive medications remained unchanged during the
study period.
A questionnaire included demographic data, sleep symptoms, med-
ical history, and medications in use. Physical examinations and anthro-
pometric measurements, including weight (in kg) and height (in m), were
recorded. Body mass index was calculated as the weight divided by the
height squared.
Polysomnograms were recorded by the Sleep Analyzer Computer
(Alice 3 Diagnostics system), including one for OSAS diagnosis and
another for positive airway pressure titration. An experienced sleep
physician scored all sleep stages (28), arousals, and respiratory events
according to American Sleep Disorders Association criteria (1, 1a).
In healthy individuals, glucocorticoid synthesis and secretion fol-
low a circadian rhythm, with the highest levels in the morning and the
nadir at around midnight. Overnight administration of dexamethasone
(DEX), a potent exogenous glucocorticoid, suppresses the nocturnal
surge in ACTH production and cortisol levels when measured the next
morning (22). Dexamethasone test is the most commonly used method
to evaluate the sensitivity of the HPA axis to negative feedback.
However, the conventional dose of 1 mg completely suppresses
cortisol secretion in normal people. For this reason, low-dose DEX
test (1 mg) has been used by some authors to induce a more modest
suppression, enabling the detection of subtle differences in feedback
sensitivity of glucocorticoid on the HPA axis (7, 15, 19, 25, 29, 33).
The assessment of the HPA axis function in this study included
low-dose (0.25 mg) DEX suppression test and the circadian rhythm of
cortisol secretion. Salivary cortisol measurement reflects the free
fraction of cortisol in plasma. Advantages are the easy and noninva-
sive collection procedure and its stability at room temperature for 7
days (5, 36, 37). The subjects were given three Salivettes (Sarstedt,
Rommelsdorf, Germany), which consist of small cotton swabs inside
centrifugation tubes used to collect saliva, and a half-tablet of 0.5 mg
DEX (Decadron, Ache´, Brazil). Salivary sample was obtained in the
morning (8:00 AM) and at bedtime, 11:00 PM, for all patients just
before the administration of DEX. The next morning, more salivary
and blood samples were collected at 8:00 AM to measure cortisol and
DEX concentrations by RIA to confirm the ingestion of the drug. To
analyze the results, we used an index of percentage of salivary cortisol
suppression (%cortisol suppression) calculated as the difference be-
tween the post-DEX cortisol levels and baseline cortisol levels at 8:00
AM divided by baseline cortisol levels at 8:00 AM.
Twenty-four-hour ambulatory blood pressure monitoring was re-
corded with a SpaceLabs model 90202 ambulatory blood pressure
monitor (Redmond, WA). An appropriately sized cuff was applied.
Blood pressure was registered every 15 min during daytime (awake)
and every 20 min during nighttime (asleep) on the basis of the
patient’s reports on their activities during day and night. The percent-
age of fall in systolic blood pressure at night was calculated by
dividing the difference between mean daytime and mean nighttime
systolic blood pressures by the mean daytime systolic blood pressure
(24). Blood pressure was considered to be controlled in those patients
with 24-h mean blood pressure values 135/85 mmHg (6).
Six patients with mild or moderate OSAS immediately underwent
bariatric surgery, and 10 patients with severe OSAS (AHI of 30
events/h of sleep) were advised to follow nasal CPAP (nCPAP)
therapy before bariatric surgery (mean nCPAP pressure of 11.2  0.7
cm of H2O) to avoid surgery complications related to sleep apnea.
One man who failed to use the device was excluded from the study
before the followup analysis. Therefore, after 3 mo of nCPAP therapy,
nine patients with severe OSAS were reassessed and all measurements
were repeated. The average nightly use of nCPAP was measured with
a run time course that ran when the patient was breathing through the
machine and not just when the machine was switched on.
This study was approved by the Univesidade Federal de Sao Paulo
Ethics Committee, and written informed consent was obtained from
all participants.
Normally distributed variables are expressed as means  SE or
percentiles when appropriate. Continuous variable comparisons be-
tween OSAS and control obese groups were performed using unpaired
Student’s t-test. Analysis of covariance tests were used to adjust
comparisons for body mass index. To assess differences between
categorical variables, we used chi-square statistics. The results before
and after nCPAP therapy were compared using paired a t-test. Cor-
relations between variables were assessed by Pearson coefficient. A
P value of 0.05 was considered statistically significant. Data
analysis was performed using SPSS for Windows version 13.0.
RESULTS
As shown in Table 1, no differences between groups for age,
body mass index, and prevalence of hypertension were ob-
served. In OSAS men, the mean 24-h heart rate was higher
(P  0.022) and the percentage fall in blood pressure during
sleep time lower compared with obese men controls (P 
0.027). Mean 24-h systolic and diastolic blood pressure values
were similar in the two groups.
Although basal salivary cortisol values at 8:00 AM (P 
0.715) and at bedtime (P  0.388) were not different between
groups, a smaller cortisol suppression post-DEX (%cortisol
suppression) was evident in OSAS patients compared with
obese controls (P 0.012) (Fig. 1). As a consequence, salivary
cortisol post-DEX was significantly higher in OSAS patients
than in obese control (P  0.038). Comparisons between
groups were adjusted for body mass index (Table. 1).
All patients had detectable circulating plasma DEX level,
indicating that all participants had ingested the DEX tablets
(Table 1). DEX levels did not differ between OSAS patients
and obese controls (84.5 9.3 vs. 101 10.5, P 0.241), and
in the total group, DEX levels did not correlate to plasma
cortisol levels post-DEX (r  0.219, P  0.328).
Three months of nCPAP therapy was associated with a
significant reduction in salivary cortisol after DEX (P 0.009)
and heart rate (P  0.036) compared with baseline. Also, a
greater cortisol suppression (%cortisol suppression) post-DEX
Table 1. Clinical and laboratorial characteristics of obese
men with and without sleep apnea
OSAS
P Value*No (n  13) Yes (n  16)
AHI, events/h 3.20.5 65.79.9 0.001
Age, yr 38.83.3 40.12.8 0.378
BMI, kg/m2 42.81.3 46.92.0 0.116
24-h SBP, mmHg 127.62.3 133.13.3 0.492
24-h DBP, mmHg 76.11.9 79.62.3 0.349
24-h Heart rate, beats/min 76.32.8 89.33.4 0.022
BP, % 11.51.8 5.51.2 0.027
Hypertension, n (%) 7 (53.8) 11 (68.8) 0.466
Salivary cortisol, ng/dl
Basal 483.977.5 442.257.5 0.715
11:00 PM 177.853.5 233.156.3 0.388
Post-DEX 233.265.6 445.461.6 0.038
%Cortisol suppression 48.810.5 16.66.1 0.012
DEX, ng/dl 10110.5 84.59.3 0.241
Plasma cortisol, 	g/dl 3.61.0 6.91.0 0.059
Data are expressed as means  SE or n (%). OSAS, obstructive sleep apnea
syndrome; AHI, apnea-hypopnea index; BMI, body mass index; SBP, systolic
blood pressure; DBP, diastolic blood pressure; BP, %fall in systolic blood
pressure at night; %cortisol suppression, cortisol post-dexamethasone (DEX)
minus cortisol basal at 8:00 AM/cortisol basal at 8:00 AM. *Significance after
adjustment for BMI.
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was evident in apneic patients following the use of nCPAP
(P  0.001). This was similar to the levels of obese controls
(Fig. 1). Average body mass index (P 0.913) did not change,
and no differences in sleep blood pressure fall and blood
pressure values were observed after nCPAP therapy (Table 2).
Six patients (67%) took antihypertensive drugs, and blood
pressure was controlled at entry.
Improvement of AHI in response to nCPAP was positively
correlated with the improvement of cortisol suppression after
oral DEX (r  0.799, P  0.010) and negatively correlated
with cortisol suppression before nCPAP (r  0.883, P 
0.002) (Fig. 2).
DISCUSSION
In the present study, we demonstrated a blunted response of
cortisol suppression after dexamethasone and a higher 24-h
heart rate in obese men with obstuctive sleep apnea syndrome
compared with obese male controls. These findings may reflect
activation of sympathetic nervous and stress system in apneic
patients, which could be due to nocturnal hypoxia and sleep
fragmentation, with several awakening and arousal episodes. In
addition, we showed a significant reduction in heart rate and a
marked improvement in dexamethasone-induced salivary cor-
tisol suppression in patients with OSAS after 3 mo of nCPAP
therapy. The reduction of apnea-hypopnea index after nCPAP
therapy was positively correlated with cortisol suppression in
response to low-dose oral dexamethasone.
Stress-related disorders such as depression, anorexia, alco-
holism, excessive exercising, malnutrition, and premenstrual
tension syndrome may be associated with increased cortico-
tropin-releasing hormone activity and ACTH secretion, result-
ing in chronic exposure to circulating cortisol levels and loss of
Fig. 2. Correlations among cortisol suppression at baseline and changes () in
cortisol suppression and in apnea-hypopnea index (AHI) following nasal
CPAP therapy.
Fig. 1. Salivary cortisol response to 0.25 mg dexamethasone (DEX) and
%cortisol suppression in obese men with and without obstructive sleep apnea
syndrome (OSAS). Data are expressed as means  SE. CPAP, continuous
positive airway pressure.
Table 2. Characteristics of men with sleep apnea before
and after 3 mo of nCPAP therapy
CPAP (n  9)
Change from
Baseline P ValuePre Post
AHI, events/h 927.6 21.19.7 70.85.3 0.001
BMI, kg/m2 44.32.4 44.42.5 0.070.70 0.913
24-h SBP, mmHg 131.53.7 125.71.9 5.73.9 0.183
24-h DBP, mmHg 77.32.5 76.02.7 1.32.9 0.665
24-h Heart rate,
beats/min 82.13.8 74.33.5 7.73.08 0.036
BP, % 6.21.9 7.31.5 1.22.1 0.440
Salivary cortisol,
ng/dl
Basal 501.189.0 521.258.6 20.189 0.827
Post-DEX 438.670.4 168.141.4 27078.4 0.009
%Cortisol
suppression 21.88.5 69.46.2 47.58.6 0.001
Data are expressed as means  SE. CPAP, continuous positive airway
pressure; nCPAP, nasal CPAP.
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the normal negative feedback of the HPA axis by glucocorti-
coids (8). In accordance with this hypothesis, it was expected
that OSAS would be associated with an activation of HPA axis
in response to stress caused by recurrent intermittent hypoxia,
sleep fragmentation, and frequent cerebral arousals during
apneic events. However, only a few studies have assessed the
relationship between sleep apnea and HPA axis, and the results
are still controversial (9, 12, 13, 18, 35). In the majority of
these studies, the HPA axis was assessed by a single morning
plasma cortisol measurement, which might not reflect the
episodic nature of cortisol secretion and its appropriate eleva-
tions during the hypoxemia stress (8). Two recent studies (9,
35) have evaluated the 24-h circadian secretory pattern of
cortisol in obese patients with and without sleep apnea. In
agreement with our results, both studies have demonstrated
that salivary and plasma cortisol secretion was circadian in
OSAS patients and obese controls. However, Dadoun et al. (9)
failed to find any significant differences for overnight cortisol
secretion between obese patients with or without sleep apnea
syndrome. Our results match those who have demonstrated that
sleep apnea in obese men is associated with increased cortisol
level during the nighttime period (11 PM to 7 AM) compared
with obese controls, which is recovered after the use of nCPAP
for 3 mo (35). Hence, we hypothesize that obstructive sleep
apnea should be recognized by clinician and corrected before
further clinical investigations of endocrine causes of hypercor-
tisolemia.
Long-term mild activation of HPA axis has been shown to
alter important functions in patients with some evidence of
hypercortisolism, i.e., adrenal incidentalomas, depression, or
alcoholism, increasing the risk for chronic conditions such
weight gain, lethargy, weakness, loss of libido, diabetes mel-
litus, hypertension, and osteoporosis (22). Thus, further pro-
spective studies should explore these clinical manifestations in
patients with OSAS and increased cortisol levels.
A positive and well-established relationship between sleep
apnea and the prevalence and severity of hypertension has been
reported (4, 14, 26, 38). Nevertheless, we did not find any
differences in 24-h blood pressure values between patients with
or without sleep apnea. Blood pressure fall during sleep,
however, was smaller in OSAS patients than in obese controls.
The reasons for these discrepancies might be the fact that, in
our study, more than one-half of patients were on hypertensive
medication, although none received -blocker therapy.
Therapy with nCPAP is the most effective treatment for
sleep apnea, preventing recurrent occlusion of the upper airway
during sleep (32). However, the effects of nCPAP on blood
pressure have shown conflicting results (1b, 3, 21). We did not
find significant changes in blood pressure levels and blood
pressure fall during sleep after nCPAP therapy in severe obese
patients with OSAS. Because our patients were under antihy-
pertensive therapy and blood pressure levels were controlled at
baseline, this may be the reason for negative results. Consistent
with our findings, Campos-Rodriguez et al. (3) reported that 24
mo of therapeutic nCPAP reduced 24-h ambulatory blood
pressure measurements only in a subgroup of patients with
incompletely controlled hypertension at baseline. They suggest
that, in a group of controlled hypertensive patients, nCPAP
therapy failed to reduce blood pressure.
Some limitations of the current study include the small
sample size and lack of a post-nCPAP treatment control group.
However, at the time of the study, sham-CPAP machines
capable of use in a double-blinded setting were not available.
Moreover, ethical approval to leave patients with severe symp-
tomatic OSAS untreated before bariatric surgery was not forth-
coming from university ethics committee.
In conclusion, our findings demonstrate that obstructive
sleep apnea syndrome is associated with increased 24-h heart
rate, decreased percentage of fall in systolic blood pressure at
night, and lower cortisol suppression after low-dose dexameth-
asone, suggesting that there is an activation of sympathetic
nervous system and HPA axis. Our results also show the
beneficial effects of nCPAP on 24-h heart rate and salivary
cortisol levels after a low-dose dexamethasone test, which may
contribute to reducing cardiovascular and metabolic complica-
tions related to OSAS.
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